Treatment of Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapy
Purpose of Review
Since the identification of multiple mutations associated with advanced non-small cell lung cancer (NSCLC), many targeted therapies have been developed for the treatment of this subgroup of lung cancers. These targeted therapies have changed the landscape of lung cancer treatment when compared to standard chemotherapy, with improved survival and quality of life. In this review article, we will review the major mutations associated with advanced NSCLC, namely EGFR, ALK, and ROS1. We will discuss their discovery, their clinical significance, and the diagnostic tests used for their detection. We will also review the respective targeted therapies developed, and the clinical trials that led to their approval.
We will also review the most recent advances in targeted therapies in the treatment of advanced NSCLC, including recent data on tyrosine kinase inhibitor osimertinib showing equal effectiveness to other first-line therapy and accordingly recommended in first line for EGFR-positive advanced NSCLC. We will discuss emerging targetable mutations such as HER2, RET, and MET.
Targeted therapies will likely shape the future of NSCLC treatment. They have been shown to provide survival advantage over chemotherapy, while providing better quality of life through ease of administration (most are oral drugs), as well as tolerability and better toxicity profile. Further elucidation of these and mutations may provide for future more effective targeted therapies.
KeywordsNon-small cell lung cancer (NSCLC) Tyrosine kinase inhibitors (TKI) Lung adenocarcinoma Anaplastic lymphoma kinase (ALK) Epidermal growth factor (EGFR) Targeted therapy C-ros mutation (ROS1) Rearranged during transfection (RET) Mesenchymal epithelial transition factor (MET) BRAF
Thanks are due to Dr. Shirin Shafazand for helping to review this paper.
Compliance with Ethical Standards
Conflict of Interest
Raja Mudad is on the advisory board for Novartis, Astra Zeneca, Takeda, and Guardant Health.
Mohamad Masri and Martine McManus declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major Importance
- 1.About Non-small cell lung cancer Am Cancer Soc 2018.Google Scholar
- 2.Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of tumours of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer; 2015.Google Scholar
- 4.Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.CrossRefPubMedGoogle Scholar
- 6.Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–59.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.•• Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/ Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018;36:1–9. The ASCO Expert Panel endorsed the CAP/IASLC/AMP molecular testing guideline with minor modifications. Google Scholar
- 15.Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, et al. The impact of common and rare EGFR mutations in response to EGFR-tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer. 2015;87:169–75.CrossRefPubMedGoogle Scholar
- 17.COSMIC database http://cancer.sanger.ac.uk/cosmic/search?q=egfr.
- 19.Non-small cell lung cancer. National Comprehensive Cancer Network NCCN Guidelines Version 1.2018.Google Scholar
- 22.Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol. 2004;22(suppl):7022–8.CrossRefGoogle Scholar
- 23.Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.CrossRefPubMedGoogle Scholar
- 24.Yang JC, Schuler MH, Yamamoto N, et al. LUX-lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol. 2012;30(18_suppl):LBA7500.CrossRefGoogle Scholar
- 25.Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–89.CrossRefPubMedGoogle Scholar
- 39.•• Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–. This trial represented a breakthrough in NSCLC-targeted therapy involving ALK mutation after decades of limitation to EGFR directed therapy–77.CrossRefPubMedGoogle Scholar
- 40.Ou SH, Bang YJ, Camidge DR, et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31(15 Suppl):8032.Google Scholar
- 41.Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol. 2012;30(15 Suppl):7508.Google Scholar
- 43.Mok T, Spigel D, Felip E, et al. ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol. 2015;33(15 Suppl):8059.Google Scholar
- 55.Lee SH, Lee JK, Ahn, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2016;28(2):292–7.Google Scholar
- 58.Camidge DR, Ou SH, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15):8001–9.Google Scholar
- 60.•• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113–25. This trial may be the first trial to reveal a newer TKI (Osimertinib) with statistically significant PFS and probably OS over standard TKI. CrossRefPubMedGoogle Scholar